D. E. Shaw & Co., Inc. - PARATEK PHARMACEUTICALS INC ownership

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of PARATEK PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$875,328
-2.5%
396,076
+12.0%
0.00%0.0%
Q1 2023$897,888
+22.3%
353,499
-10.0%
0.00%0.0%
Q4 2022$734,341
-7.6%
392,696
+26.9%
0.00%0.0%
Q3 2022$795,000
+248.7%
309,564
+161.9%
0.00%
Q2 2022$228,0000.0%118,209
+53.7%
0.00%
Q1 2022$228,000
+78.1%
76,931
+170.8%
0.00%
Q4 2021$128,000
-52.6%
28,413
-48.8%
0.00%
Q3 2021$270,000
-63.0%
55,507
-48.1%
0.00%
-100.0%
Q2 2021$729,000
-52.4%
106,908
-50.7%
0.00%0.0%
Q1 2021$1,530,000
-38.2%
216,653
-45.2%
0.00%
-50.0%
Q4 2020$2,477,000
-25.5%
395,661
-35.6%
0.00%
-33.3%
Q3 2020$3,325,000
-37.5%
614,554
-39.7%
0.00%
-50.0%
Q2 2020$5,316,000
+200.8%
1,018,465
+81.5%
0.01%
+100.0%
Q1 2020$1,767,000
+68.6%
561,124
+115.7%
0.00%
+200.0%
Q4 2019$1,048,000
+1243.6%
260,083
+1343.3%
0.00%
Q3 2019$78,000
-78.3%
18,020
-10.2%
0.00%
Q4 2017$359,000
+116.3%
20,071
+85.7%
0.00%
Q4 2016$166,000
-40.5%
10,806
-49.6%
0.00%
Q3 2016$279,000
-92.6%
21,456
-78.2%
0.00%
-100.0%
Q4 2014$3,790,00098,3150.01%
Other shareholders
PARATEK PHARMACEUTICALS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Omega Fund Management, LLC 2,600,410$36,172,00026.83%
Abingworth LLP 1,301,413$18,103,00018.96%
Roumell Asset Management, LLC 290,136$4,036,0009.16%
Monashee Investment Management LLC 100,000$1,391,0002.19%
BVF INC/IL 575,000$7,998,0001.70%
Aisling Capital LLC 482,680$6,714,0001.59%
Opaleye Management Inc. 146,700$2,041,0001.36%
Broadfin Capital, LLC 803,332$11,174,0001.09%
GENERAL AMERICAN INVESTORS CO INC 477,076$6,636,0000.69%
Opus Point Partners Management, LLC 37,665$524,0000.51%
View complete list of PARATEK PHARMACEUTICALS INC shareholders